APCCC 2026

Viewing 1-20 of 56 articles

APCCC 2026: Which Patients Planned for Salvage Radiotherapy Need Systemic Therapy and for How Long?

APCCC 2026: How to Test for Relevant Molecular Alterations in mHSPC?

APCCC 2026: Debate: Early Salvage Radiotherapy Is Equivalent to Adjuvant Radiotherapy in Patients with High-Risk Localized or Locally Advanced Disease: Con

APCCC 2026: Are There Patients with mCRPC Who May Benefit from Immunotherapy?

APCCC 2026: Neuroendocrine Prostate Cancer - Treatment Options in 2026 and Hope for New Treatments?

APCCC 2026: Oligometastatic CRPC – What Is the Evidence for SBRT?

APCCC 2026: PSA Recurrence After Radiotherapy – When and How to React?

APCCC 2026: Debate: Early Salvage Radiotherapy Is Equivalent to Adjuvant Radiotherapy in Patients with High-Risk Localized or Locally Advanced Disease: Pro

APCCC 2026: How to Select Patients with mHSPC for ADT plus an ARPI plus a Targeted Therapy (PARP or AKT Inhibition)?

APCCC 2026: What to Expect from Androgen Receptor Antagonist Monotherapy in Terms of Side-Effects and HRQoL?

APCCC 2026: Bone Protection in Patients with HSPC Starting on Long-Term ADT and in Patients with mCRPC

APCCC 2026: What Is the Evidence for Using Metformin in Advanced Prostate Cancer?

APCCC 2026: Monitoring in mCRPC

APCCC 2026: Is There a Role for the Routine Use of ctDNA in Advanced Prostate Cancer?

APCCC 2026: How to Make Best Use of Lutetium-PSMA Radioligand Therapy?

APCCC 2026: How to Optimally Select Patients for Lutetium-PSMA Radioligand Therapy?

APCCC 2026: How Can Electronic Tools Be Used for Monitoring of Patients with Advanced Prostate Cancer?

APCCC 2026: How to Optimally Select Patients for Radionuclide Therapy with Radium-223?

APCCC 2026: Monitoring in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

APCCC 2026: Beyond PSMA: New Theranostic Targets Approaching near Term Clinical Implementation

1
2
3